News
-
-
PRESS RELEASE
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Transgene and BioInvent present promising early results of oncolytic virus BT-001 in ESMO 2024, showing antitumor activity in solid tumors. BT-001 induces tumor regression and enhances T cell infiltration -
-
-
-
-
PRESS RELEASE
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
Transgene announces preclinical proof-of-concept data of oncolytic virus TG6050 published in JITC, showcasing tumor regression and immune remodeling capabilities without systemic toxicity. TG6050 progressing in Phase I trial for NSCLC -
-
-
PRESS RELEASE
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025